Tags

Type your tag names separated by a space and hit enter

Impairment of the in vitro release of carbamazepine from tablets.
Bosn J Basic Med Sci. 2010 Aug; 10(3):234-8.BJ

Abstract

Carbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formulations of immediate release tablets of poorly soluble carbamazepine. As model tablets for this investigation, two formulations (named "A" and "B" formulations) of carbamazepine tablets labeled to contain 200 mg were evaluated. The aim of this study was to establish possible differences in dissolution profile of these two formulations purchased from the local market. The increased crystallinity together with enlarged particle size, enhanced aggregation and decreased wettability of the drug, resulted in insufficient dissolution rate for formulation "B". From the dissolution point of view, this formulation was inferior to the formulation "A", due to the solubilization effect.

Links

PMC Free PDF
PMC Free Full Text

Authors+Show Affiliations

Uzunović A
Agency for Medical Products and Medical Devices of Bosnia and Herzegovina, Titova 9, 71000 Sarajevo, Bosnia And Herzegovina.
Vranić E
No affiliation info available
Hadzidedić S
No affiliation info available

MeSH

Analgesics, Non-NarcoticAnticonvulsantsArea Under CurveBiological AvailabilityCarbamazepineChemistry, PharmaceuticalExcipientsIndicators and ReagentsParticle SizeReference StandardsSolubilityTablets

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20846131

Citation

Uzunović, Alija, et al. "Impairment of the in Vitro Release of Carbamazepine From Tablets." Bosnian Journal of Basic Medical Sciences, vol. 10, no. 3, 2010, pp. 234-8.
Uzunović A, Vranić E, Hadzidedić S. Impairment of the in vitro release of carbamazepine from tablets. Bosn J Basic Med Sci. 2010;10(3):234-8.
Uzunović, A., Vranić, E., & Hadzidedić, S. (2010). Impairment of the in vitro release of carbamazepine from tablets. Bosnian Journal of Basic Medical Sciences, 10(3), 234-8.
Uzunović A, Vranić E, Hadzidedić S. Impairment of the in Vitro Release of Carbamazepine From Tablets. Bosn J Basic Med Sci. 2010;10(3):234-8. PubMed PMID: 20846131.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impairment of the in vitro release of carbamazepine from tablets. AU - Uzunović,Alija, AU - Vranić,Edina, AU - Hadzidedić,Seherzada, PY - 2010/9/18/entrez PY - 2010/9/18/pubmed PY - 2011/1/8/medline SP - 234 EP - 8 JF - Bosnian journal of basic medical sciences JO - Bosn J Basic Med Sci VL - 10 IS - 3 N2 - Carbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formulations of immediate release tablets of poorly soluble carbamazepine. As model tablets for this investigation, two formulations (named "A" and "B" formulations) of carbamazepine tablets labeled to contain 200 mg were evaluated. The aim of this study was to establish possible differences in dissolution profile of these two formulations purchased from the local market. The increased crystallinity together with enlarged particle size, enhanced aggregation and decreased wettability of the drug, resulted in insufficient dissolution rate for formulation "B". From the dissolution point of view, this formulation was inferior to the formulation "A", due to the solubilization effect. SN - 1840-4812 UR - https://www.unboundmedicine.com/medline/citation/20846131/Impairment_of_the_in_vitro_release_of_carbamazepine_from_tablets_ L2 - https://doi.org/10.17305/bjbms.2010.2693 DB - PRIME DP - Unbound Medicine ER -